亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

医学 卡铂 吉西他滨 彭布罗利珠单抗 安慰剂 多西紫杉醇 三阴性乳腺癌 内科学 肿瘤科 乳腺癌 化疗 紫杉烷 癌症 转移性乳腺癌 免疫疗法 顺铂 病理 替代医学
作者
Javier Cortés,David W. Cescon,Hope S. Rugo,Zbigniew Ireneusz Nowecki,Seock‐Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos H. Barrios,Esther Holgado,Hiroji Iwata,Norikazu Masuda,Marco Torregroza Otero,Erhan Gökmen,Sherene Loi,Zifang Guo,Jing Zhao,Gursel Aktan,Vassiliki Karantza,Peter Schmid
出处
期刊:The Lancet [Elsevier BV]
卷期号:396 (10265): 1817-1828 被引量:1847
标识
DOI:10.1016/s0140-6736(20)32531-9
摘要

Summary

Background

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.

Methods

In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomisation was stratified by type of on-study chemotherapy (taxane or gemcitabine–carboplatin), PD-L1 expression at baseline (combined positive score [CPS] ≥1 or <1), and previous treatment with the same class of chemotherapy in the neoadjuvant or adjuvant setting (yes or no). Eligibility criteria included age at least 18 years, centrally confirmed triple-negative breast cancer; at least one measurable lesion; provision of a newly obtained tumour sample for determination of triple-negative breast cancer status and PD-L1 status by immunohistochemistry at a central laboratory; an Eastern Cooperative Oncology Group performance status score 0 or 1; and adequate organ function. The sponsor, investigators, other study site staff (except for the unmasked pharmacist), and patients were masked to pembrolizumab versus saline placebo administration. In addition, the sponsor, the investigators, other study site staff, and patients were masked to patient-level tumour PD-L1 biomarker results. Dual primary efficacy endpoints were progression-free survival and overall survival assessed in the PD-L1 CPS of 10 or more, CPS of 1 or more, and intention-to-treat populations. The definitive assessment of progression-free survival was done at this interim analysis; follow-up to assess overall survival is continuing. For progression-free survival, a hierarchical testing strategy was used, such that testing was done first in patients with CPS of 10 or more (prespecified statistical criterion was α=0·00411 at this interim analysis), then in patients with CPS of 1 or more (α=0·00111 at this interim analysis, with partial alpha from progression-free survival in patients with CPS of 10 or more passed over), and finally in the intention-to-treat population (α=0·00111 at this interim analysis). This study is registered with ClinicalTrials.gov, NCT02819518, and is ongoing.

Findings

Between Jan 9, 2017, and June 12, 2018, of 1372 patients screened, 847 were randomly assigned to treatment, with 566 patients in the pembrolizumab–chemotherapy group and 281 patients in the placebo–chemotherapy group. At the second interim analysis (data cutoff, Dec 11, 2019), median follow-up was 25·9 months (IQR 22·8–29·9) in the pembrolizumab–chemotherapy group and 26·3 months (22·7–29·7) in the placebo–chemotherapy group. Among patients with CPS of 10 or more, median progression-free survival was 9·7 months with pembrolizumab–chemotherapy and 5·6 months with placebo–chemotherapy (hazard ratio [HR] for progression or death, 0·65, 95% CI 0·49–0·86; one-sided p=0·0012 [primary objective met]). Median progression-free survival was 7·6 and 5·6 months (HR, 0·74, 0·61–0·90; one-sided p=0·0014 [not significant]) among patients with CPS of 1 or more and 7·5 and 5·6 months (HR, 0·82, 0·69–0·97 [not tested]) among the intention-to-treat population. The pembrolizumab treatment effect increased with PD-L1 enrichment. Grade 3–5 treatment-related adverse event rates were 68% in the pembrolizumab–chemotherapy group and 67% in the placebo–chemotherapy group, including death in <1% in the pembrolizumab–chemotherapy group and 0% in the placebo–chemotherapy group.

Interpretation

Pembrolizumab–chemotherapy showed a significant and clinically meaningful improvement in progression-free survival versus placebo–chemotherapy among patients with metastatic triple-negative breast cancer with CPS of 10 or more. These findings suggest a role for the addition of pembrolizumab to standard chemotherapy for the first-line treatment of metastatic triple-negative breast cancer.

Funding

Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧郁的涵雁完成签到 ,获得积分10
24秒前
51秒前
54秒前
lingrong发布了新的文献求助10
58秒前
M.发布了新的文献求助10
59秒前
M.完成签到,获得积分10
1分钟前
1分钟前
酷波er的应助被lingrong采纳,获得10
1分钟前
佳言2009完成签到 ,获得积分10
1分钟前
负责的初柔完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被张阳采纳,获得10
1分钟前
1分钟前
1分钟前
yyzc6162发布了新的文献求助10
1分钟前
慕容杏子完成签到 ,获得积分10
1分钟前
1分钟前
MchemG的应助被科研通管家采纳,获得30
1分钟前
MchemG的应助被科研通管家采纳,获得30
1分钟前
1分钟前
2分钟前
清爽友蕊发布了新的文献求助10
2分钟前
张阳发布了新的文献求助10
2分钟前
在水一方的应助被amiee采纳,获得10
2分钟前
2分钟前
2分钟前
yyzc6162完成签到,获得积分10
2分钟前
amiee发布了新的文献求助10
2分钟前
忧虑的如雪完成签到,获得积分10
2分钟前
完美世界的应助被清爽友蕊采纳,获得10
2分钟前
犹豫擎苍完成签到,获得积分10
3分钟前
adefgv完成签到,获得积分10
3分钟前
3分钟前
fhjg完成签到,获得积分10
3分钟前
3分钟前
jtk完成签到,获得积分10
3分钟前
pwn完成签到,获得积分10
3分钟前
3分钟前
3分钟前
彭于晏的应助被科研通管家采纳,获得10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190127
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852194
捐赠科研通 7788458
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560003
邀请新用户注册赠送积分活动 2482880